Pfizer's Parecoxib Ad Cited By U.K. For Using Out-Of-Date Labeling
This article was originally published in The Pink Sheet Daily
Executive Summary
A journal ad for parecoxib, marketed as Dynastat in the U.K., did not mention two warnings recently added to the COX-2 inhibitor for use in congestive heart failure and coronary artery bypass graft patients. The Medicines & Healthcare Products Regulatory Agency is requesting a corrective statement. The parecoxib NDA is pending at FDA.
You may also be interested in...
Merck Withdraws Fosamax UK Ad Claiming Superiority To Generic
UK Merck subsidiary issues corrective statement acknowledging no superiority over Teva’s generic alendronic acid, as required by the British Medicines & Healthcare products Regulatory Agency.
Merck Withdraws Fosamax UK Ad Claiming Superiority To Generic
UK Merck subsidiary issues corrective statement acknowledging no superiority over Teva’s generic alendronic acid, as required by the British Medicines & Healthcare products Regulatory Agency.
Pfizer Zoloft Ad Cited By FDA For Omitting Suicide Risk
FDA's ad review division objects to an October print ad for the antidepressant that failed to mention the risk of suicidality and clinical worsening. The ad's brief summary referenced information from outdated labeling, the agency says.